EEF2K (Eukaryotic Elongation Factor 2 Kinase) is a unique calcium/calmodulin-dependent kinase that regulates protein synthesis by phosphorylating eukaryotic elongation factor 2 (eEF2). Unlike conventional protein kinases, EEF2K belongs to the α-kinase family and represents a distinct branch of the protein kinase superfamily [1]. The enzyme is encoded by the EEF2K gene located on chromosome 16p13.3 and is widely expressed in human tissues, with particular importance in the brain where it regulates translation elongation in response to cellular signals.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
| Symbol | EEF2K |
|---|
| Full Name | Eukaryotic Elongation Factor 2 Kinase |
|---|
| Aliases | eEF-2 kinase, CaMKIII, Calcium/Calmodulin-dependent kinase III |
|---|
| Chromosomal Location | Chr16p13.3 |
|---|
| NCBI Gene ID | 29945 |
|---|
| Ensembl ID | ENSG00000103319 |
|---|
| UniProt ID | Q9UII2 |
|---|
| Associated Diseases | Alzheimer's disease, Parkinson's disease, Cancer, Diabetes |
|---|
¶ Protein Structure and Function
¶ Domain Architecture
EEF2K is a 724-amino acid protein with a unique domain organization [2]:
- N-terminal Regulatory Domain: Contains the calcium/calmodulin-binding region
- Kinase Domain: The catalytic α-kinase domain in the C-terminal region
- Autoinhibitory Region: Regulates enzyme activity in response to cellular signals
The α-kinase domain is structurally distinct from conventional protein kinases, with a different ATP-binding pocket and catalytic mechanism. This uniqueness makes EEF2K an attractive target for drug development.
EEF2K participates in several critical cellular processes:
- eEF2 Phosphorylation: EEF2K phosphorylates eEF2 on threonine 56, inhibiting translation elongation [3]
- Stress Response: The enzyme is a key mediator of the integrated stress response (ISR)
- Autophagy Regulation: EEF2K links translation inhibition to autophagy induction
- Metabolic Control: Regulates cellular energy expenditure through translation control
EEF2K activity is regulated by multiple mechanisms:
- Calcium/Calmodulin Binding: Primary activation mechanism
- AMP-Activated Protein Kinase (AMPK): Phosphorylates and activates EEF2K during energy stress
- mTORC1 Signaling: Inhibits EEF2K through S6K-mediated phosphorylation
- Sustained ERK Activation: Leads to EEF2K activation
EEF2K interacts with multiple signaling pathways:
- eEF2: Primary substrate, phosphorylation inhibits elongation
- AMPK: Energy sensor that activates EEF2K
- mTORC1: Growth signaling that inhibits EEF2K
- ERK/MAPK Pathway: Stress-activated signaling that activates EEF2K
EEF2K is ubiquitously expressed in human tissues with highest expression in:
- Brain: Particularly in neurons of the cortex, hippocampus, and cerebellum
- Heart: High expression in cardiac muscle
- Skeletal Muscle: Significant expression in muscle fibers
- Pancreas: Moderate expression in pancreatic β-cells
In neurons, EEF2K is localized to both the cell body and dendritic compartments, where it regulates local translation in response to synaptic activity.
EEF2K has been extensively studied in Alzheimer's disease pathogenesis [4]:
- Synaptic Protein Synthesis Deficits: EEF2K hyperactivity contributes to reduced synaptic protein synthesis in AD
- Tau Pathology: Altered eEF2 phosphorylation affects tau phosphorylation and aggregation
- Amyloid-β Effects: Aβ exposure activates EEF2K, contributing to translational repression
- Memory Impairment: EEF2K-mediated translational control is critical for memory consolidation
In Parkinson's disease, EEF2K contributes to:
- Dopaminergic Neuron Survival: EEF2K activity affects viability of dopaminergic neurons
- α-Synuclein Toxicity: Translational dysregulation contributes to protein aggregation
- Mitochondrial Dysfunction: EEF2K links cellular stress to translational control
EEF2K has been implicated in ALS through:
- Motor Neuron Vulnerability: Altered translation regulation affects motor neuron survival
- Stress Response: EEF2K mediates cellular stress responses in motor neurons
- Protein Aggregate Clearance: Autophagy induction affects aggregate clearance
In Huntington's disease:
- Translation Dysregulation: EEF2K contributes to altered protein synthesis
- Neuronal Dysfunction: Regulates survival pathways in medium spiny neurons
- Therapeutic Target: EEF2K inhibition shows promise in preclinical models
When EEF2K phosphorylates eEF2:
- Ribosome translocation is blocked
- Polysomes disassemble
- Synaptic protein synthesis is reduced
- Long-term memory formation is impaired
EEF2K is a key mediator of the ISR [5]:
- Cellular stresses activate EEF2K
- Global translation is repressed
- Selective translation of stress response proteins occurs
- Prolonged activation leads to apoptosis
EEF2K links translation to autophagy:
- Translation inhibition triggers autophagy
- Autophagy clears damaged proteins and organelles
- Failure of this pathway contributes to neurodegeneration
Multiple EEF2K inhibitors have been developed and tested [6]:
- NH125: First-generation EEF2K inhibitor
- A-484954: More specific inhibitor with better cellular activity
- AX20017: Clinical candidate for neurodegenerative disease
- Memory Enhancement: EEF2K inhibition improves memory in preclinical models
- Neuroprotection: Blocking EEF2K protects neurons from various insults
- Cancer Therapy: EEF2K inhibition sensitizes cancer cells to treatment
- Blood-Brain Barrier Penetration: Developing brain-penetrant inhibitors
- Selectivity: Achieving specificity for EEF2K over other kinases
- Chronic vs. Acute Effects: Understanding long-term consequences of inhibition
- Western Blotting: Measure eEF2 phosphorylation levels
- Kinase Assays: Measure EEF2K enzymatic activity
- Polysome Profiling: Assess translation elongation status
- Neuronal Culture: Study EEF2K in differentiated neurons
- Live Cell Imaging: Monitor translation in real time
- Electrophysiology: Assess synaptic function
- Knockout Mice: Reveal developmental and physiological consequences
- Conditional Knockouts: Study tissue-specific EEF2K function
- Behavioral Tests: Memory and learning assessments
- Biomarker Development: eEF2 phosphorylation as a biomarker
- Therapeutic Trials: Test EEF2K inhibitors in patients
- Genetic Studies: Identify EEF2K variants in disease